Literature DB >> 15714511

Pathophysiology of spastic paresis. II: Emergence of muscle overactivity.

Jean-Michel Gracies1.   

Abstract

In the subacute and chronic stages of spastic paresis, stretch-sensitive (spastic) muscle overactivity emerges as a third fundamental mechanism of motor impairment, along with paresis and soft tissue contracture. Part II of this review primarily addresses the pathophysiology of the various forms of spastic overactivity. It is argued that muscle contracture is one of the factors that cause excessive responsiveness to stretch, which in turn aggravates contracture. Excessive responsiveness to stretch also impedes voluntary motor neuron recruitment, a concept termed stretch-sensitive paresis. None of the three mechanisms of impairment (paresis, contracture, and spastic overactivity) is symmetrically distributed between agonists and antagonists, which generates torque imbalance around joints and limb deformities. Thus, each may be best treated focally on an individual muscle-by-muscle basis. Intensive motor training of the less overactive muscles should disrupt the cycle of paresis-disuse-paresis, and concomitant use of aggressive stretch and focal weakening agents in their more overactive and shortened antagonists should break the cycle of overactivity-contracture-overactivity.

Entities:  

Mesh:

Year:  2005        PMID: 15714511     DOI: 10.1002/mus.20285

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  78 in total

1.  Contributions of altered stretch reflex coordination to arm impairments following stroke.

Authors:  Randy D Trumbower; Vengateswaran J Ravichandran; Matthew A Krutky; Eric J Perreault
Journal:  J Neurophysiol       Date:  2010-10-20       Impact factor: 2.714

2.  The nature of hand motor impairment after stroke and its treatment.

Authors:  Preeti Raghavan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06

Review 3.  New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy.

Authors:  Diane L Damiano; Katharine E Alter; Henry Chambers
Journal:  Phys Med Rehabil Clin N Am       Date:  2009-08       Impact factor: 1.784

4.  Clinician's Commentary on Cheung et al.(1).

Authors:  Parvin Eftekhar
Journal:  Physiother Can       Date:  2015       Impact factor: 1.037

5.  Electrodiagnostic and nerve ultrasonographic features in upper limb spasticity: an observational study.

Authors:  A Picelli; S Tamburin; G Berto; E Chemello; Marialuisa Gandolfi; Leopold Saltuari; Andreas Waldner; Nicola Smania
Journal:  Funct Neurol       Date:  2017 Jul/Sep

6.  Cortical and spinal excitability changes after repetitive transcranial magnetic stimulation combined to physiotherapy in stroke spastic patients.

Authors:  Rebeka Borba Costa Dos Santos; Silvana Carla Barros Galvão; Labibe Mara Pinel Frederico; Nathália Serrano Lucena Amaral; Maíra Izzadora Souza Carneiro; Alberto Galvão de Moura Filho; Daniele Piscitelli; Kátia Monte-Silva
Journal:  Neurol Sci       Date:  2019-03-09       Impact factor: 3.307

Review 7.  Botulinum Toxin Treatment in Multiple Sclerosis-a Review.

Authors:  Yasaman Safarpour; Tahereh Mousavi; Bahman Jabbari
Journal:  Curr Treat Options Neurol       Date:  2017-08-17       Impact factor: 3.598

8.  Botulinum toxin injection causes hyper-reflexia and increased muscle stiffness of the triceps surae muscle in the rat.

Authors:  Jessica Pingel; Jacob Wienecke; Jakob Lorentzen; Jens Bo Nielsen
Journal:  J Neurophysiol       Date:  2016-09-14       Impact factor: 2.714

9.  Stretch reflex coupling between the hip and knee: implications for impaired gait following stroke.

Authors:  James M Finley; Eric J Perreault; Yasin Y Dhaher
Journal:  Exp Brain Res       Date:  2008-04-30       Impact factor: 1.972

10.  Comparing unilateral and bilateral upper limb training: the ULTRA-stroke program design.

Authors:  A Lex E Q van Delden; C Lieke E Peper; Jaap Harlaar; Andreas Daffertshofer; Nienke I Zijp; Kirsten Nienhuys; Peter Koppe; Gert Kwakkel; Peter J Beek
Journal:  BMC Neurol       Date:  2009-11-06       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.